Open AccessASSOCIATION BETWEEN HIGH-RISK DISEASE LOCI AND RESPONSE TO ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR WET AGE-RELATED MACULAR DEGENERATION
Author(s) -
Anton Orlin,
Dexter Hadley,
Woo Hyok Chang,
Allen C. Ho,
Gary C. Brown,
Richard Kaiser,
Carl D. Regillo,
Ashlee N. Godshalk,
Audun Lier,
Brian Kaderli,
Dwight Stambolian
Publication year - 2012
Publication title -
retina
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.24
H-Index - 120
eISSN - 1539-2864
pISSN - 0275-004X
DOI - 10.1097/iae.0b013e31822a2c7c
Subject(s) - ranibizumab , macular degeneration , medicine , bevacizumab , visual acuity , vascular endothelial growth factor , cohort , retrospective cohort study , ophthalmology , single nucleotide polymorphism , genotype , gastroenterology , oncology , chemotherapy , vegf receptors , gene , biology , genetics
To investigate whether there is an association between known age-related macular degeneration genetic risk variants in the CFH, ARMS2, and HTRA1 genes and response to anti-vascular endothelial growth factor (VEGF) (ranibizumab or bevacizumab) treatment for wet age-related macular degeneration.